Bibliography
- Pritchard NR, Smith KG. B cell inhibitory receptors and autoimmunity. Immunology 2003;108:263-73
- Wright GJ, Jones M, Puklavec MJ, The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001;102:173-9
- Rijkers ESK, De Ruiter T, Baridi A, The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol 2008;45:1126-35
- Zhang S, Phillips JH. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol 2006;79:363-8
- Karnam G, Rygiel TP, Raaben M, CD200 receptor controls sex-specific TLR7 responses to viral infection. PLoS Pathog 2012;8:e1002710
- Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 2004;173:6786-93
- Mihrshahi R, Barclay AN, Brown MH. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol 2009;183:4879-86
- Mihrshahi R, Brown MH. Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling. J Immunol 2010;185:7216-22
- Hoek RM, Ruuls SR, Murphy CA, Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000;290:1768-71
- Rygiel TP, Rijkers ES, De Ruiter T, Lack of CD200 enhances pathological T cell responses during influenza infection. J Immunol 2009;183:1990-6
- Snelgrove RJ, Goulding J, Didierlaurent AM, A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008;9:1074-83
- Mukhopadhyay S, Pluddemann A, Hoe JC, Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. Cell Host Microbe 2010;8:236-47
- Kretz-Rommel A, Qin F, Dakappagari N, CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007;178:5595-605
- Rygiel TP, Meyaard L. CD200R signaling in tumor tolerance and inflammation: a tricky balance. Curr Opin Immunol 2012;24:233-8
- Gorczynski RM, Cattral MS, Chen Z, An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 1999;163:1654-60
- Gorczynski RM. Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages. Eur J Immunol 2001;31:2331-7
- Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 2005;79:1180-3
- Gorczynski RM, Chen Z, He W, Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 2009;183:1560-8
- Yu K, Gorczynski RM. Persistence of gene expression profile in CD200 transgenic skin allografts is associated with graft survival on retransplantation to normal recipients. Transplantation 2012;94:36-42
- Rygiel TP, Karnam G, Goverse G, CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor. Oncogene 2011;31:2979-88
- Wang JW, Howson JM, Ghansah T, Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 2002;295:2094-7
- Kerr WG. A role for SHIP in stem cell biology and transplantation. Curr Stem Cell Res Ther 2008;3:99-106
- Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol 2010;125:S324-35
- Lunsford KE, Barbas AS, Brennan TV. Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. Curr Opin Organ Transplant 2011;16:390-7
- Kho M, Cransberg K, Weimar W, van Gelder T. Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother 2011;12:1217-31
- Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011;91:1057-64